NeoGenomics appoints Robert Shovlin as chief operating officer

30 September 2014

Cancer-focused genetic testing service provider NeoGenomics (Nasdaq: NEO) has appointed Robert Shovlin as chief operating officer.

Between 2012 and his appointment at NeoGenomics, he has served as chief development officer for Bostwick Laboratories, which provides anatomic pathology testing. From 2005 to 2011 he served in positions of increasing responsibility, up to president and chief executive, at Aureon Biosciences, a venture-backed diagnostics company focused on prostate cancer tests.

Douglas VanOort, chairman and chief executive of NeoGenomics, said: "We are delighted to welcome Rob to our company. Rob's strong experience and leadership in the clinical laboratory testing industry, and particularly in anatomic pathology, will be invaluable to us as we expand our business over the next few years, and we are very excited to have Rob join our team."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >